JP2022505604A5 - - Google Patents
Info
- Publication number
- JP2022505604A5 JP2022505604A5 JP2021522004A JP2021522004A JP2022505604A5 JP 2022505604 A5 JP2022505604 A5 JP 2022505604A5 JP 2021522004 A JP2021522004 A JP 2021522004A JP 2021522004 A JP2021522004 A JP 2021522004A JP 2022505604 A5 JP2022505604 A5 JP 2022505604A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- amino acid
- seq
- antigen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024019151A JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗ｎｐｒ１抗体およびその使用 |
| JP2025116272A JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗ｎｐｒ１抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862749557P | 2018-10-23 | 2018-10-23 | |
| US62/749,557 | 2018-10-23 | ||
| US201862755720P | 2018-11-05 | 2018-11-05 | |
| US62/755,720 | 2018-11-05 | ||
| PCT/US2019/057033 WO2020086406A2 (en) | 2018-10-23 | 2019-10-18 | Anti-npr1 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019151A Division JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗ｎｐｒ１抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022505604A JP2022505604A (ja) | 2022-01-14 |
| JP2022505604A5 true JP2022505604A5 (enExample) | 2022-10-24 |
| JP7439076B2 JP7439076B2 (ja) | 2024-02-27 |
Family
ID=68732036
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522004A Active JP7439076B2 (ja) | 2018-10-23 | 2019-10-18 | 抗ｎｐｒ１抗体およびその使用 |
| JP2024019151A Active JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗ｎｐｒ１抗体およびその使用 |
| JP2025116272A Pending JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗ｎｐｒ１抗体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024019151A Active JP7713051B2 (ja) | 2018-10-23 | 2024-02-13 | 抗ｎｐｒ１抗体およびその使用 |
| JP2025116272A Pending JP2025148445A (ja) | 2018-10-23 | 2025-07-10 | 抗ｎｐｒ１抗体およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US11306148B2 (enExample) |
| EP (1) | EP3870612A2 (enExample) |
| JP (3) | JP7439076B2 (enExample) |
| KR (1) | KR20210082207A (enExample) |
| CN (1) | CN112805303B (enExample) |
| AU (1) | AU2019368196B2 (enExample) |
| CA (1) | CA3115102A1 (enExample) |
| CL (3) | CL2021000942A1 (enExample) |
| CO (1) | CO2021006663A2 (enExample) |
| IL (1) | IL281297B1 (enExample) |
| MX (2) | MX2021004284A (enExample) |
| MY (1) | MY205168A (enExample) |
| PH (1) | PH12021550255A1 (enExample) |
| SG (1) | SG11202101037QA (enExample) |
| WO (1) | WO2020086406A2 (enExample) |
| ZA (1) | ZA202100714B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| US11066469B2 (en) | 2019-06-12 | 2021-07-20 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| US12281161B2 (en) | 2021-07-28 | 2025-04-22 | Trustees Of Boston University | Polypeptides and uses thereof |
| CN118159290A (zh) | 2021-10-11 | 2024-06-07 | 瑞泽恩制药公司 | 通过施用抗npr1抗体来影响血液动力学变化的方法 |
| JP2024542823A (ja) * | 2021-12-06 | 2024-11-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンタゴニスト抗ｎｐｒ１抗体およびその使用方法 |
| WO2023187657A1 (en) | 2022-03-30 | 2023-10-05 | Novartis Ag | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies |
| AU2024287056A1 (en) * | 2023-06-08 | 2025-12-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-npr1 antibody and pharmaceutical use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| JP5307708B2 (ja) | 2006-06-02 | 2013-10-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒトｉｌ−６受容体に対する高親和性抗体 |
| US20100310561A1 (en) * | 2007-06-06 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Natriuretic fusion proteins |
| WO2010065293A1 (en) | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| AU2010273585B2 (en) | 2009-07-13 | 2015-04-23 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| US10184942B2 (en) * | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| US9451770B2 (en) | 2012-06-08 | 2016-09-27 | Charles Despres | Method of activating immune response in plants |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| WO2016131943A1 (en) * | 2015-02-20 | 2016-08-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity and complications arising therefrom including type 2 diabetes |
| WO2017209553A2 (ko) | 2016-06-03 | 2017-12-07 | 사회복지법인 삼성생명공익재단 | 환자 유래 세포를 이용한 항체 스크리닝 방법 |
| US20190248888A1 (en) * | 2016-10-20 | 2019-08-15 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
| US20190135804A1 (en) | 2017-11-03 | 2019-05-09 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Compositions and methods for the inhibition of pruritus |
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| EP3898700A1 (en) | 2018-12-18 | 2021-10-27 | Novartis AG | Reversal binding agents for anti-factor xi/xia antibodies and uses thereof |
| US11066469B2 (en) | 2019-06-12 | 2021-07-20 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| JP2024542823A (ja) | 2021-12-06 | 2024-11-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンタゴニスト抗ｎｐｒ１抗体およびその使用方法 |
-
2019
- 2019-10-18 KR KR1020217015469A patent/KR20210082207A/ko active Pending
- 2019-10-18 MY MYPI2021001138A patent/MY205168A/en unknown
- 2019-10-18 CN CN201980065187.4A patent/CN112805303B/zh active Active
- 2019-10-18 US US16/657,000 patent/US11306148B2/en active Active
- 2019-10-18 MX MX2021004284A patent/MX2021004284A/es unknown
- 2019-10-18 JP JP2021522004A patent/JP7439076B2/ja active Active
- 2019-10-18 WO PCT/US2019/057033 patent/WO2020086406A2/en not_active Ceased
- 2019-10-18 SG SG11202101037QA patent/SG11202101037QA/en unknown
- 2019-10-18 AU AU2019368196A patent/AU2019368196B2/en active Active
- 2019-10-18 CA CA3115102A patent/CA3115102A1/en active Pending
- 2019-10-18 EP EP19812875.3A patent/EP3870612A2/en active Pending
-
2021
- 2021-02-02 ZA ZA2021/00714A patent/ZA202100714B/en unknown
- 2021-02-03 PH PH12021550255A patent/PH12021550255A1/en unknown
- 2021-03-07 IL IL281297A patent/IL281297B1/en unknown
- 2021-04-14 MX MX2024011444A patent/MX2024011444A/es unknown
- 2021-04-15 CL CL2021000942A patent/CL2021000942A1/es unknown
- 2021-05-21 CO CONC2021/0006663A patent/CO2021006663A2/es unknown
-
2022
- 2022-03-10 US US17/692,084 patent/US11820826B2/en active Active
-
2023
- 2023-05-12 CL CL2023001377A patent/CL2023001377A1/es unknown
- 2023-10-11 US US18/485,241 patent/US20240059780A1/en not_active Abandoned
-
2024
- 2024-02-07 CL CL2024000378A patent/CL2024000378A1/es unknown
- 2024-02-13 JP JP2024019151A patent/JP7713051B2/ja active Active
- 2024-05-31 US US18/680,910 patent/US20240309103A1/en active Pending
-
2025
- 2025-07-10 JP JP2025116272A patent/JP2025148445A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022505604A5 (enExample) | ||
| TWI689518B (zh) | 特異性結合人ｉｌ-１７ａ的分離的單株抗體 | |
| JP2018108081A5 (enExample) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| IL292780A (en) | A new 4-1bbl trimer containing antigen-binding molecules | |
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| JP2021526534A5 (enExample) | ||
| JP2010501164A5 (enExample) | ||
| CN112805303A (zh) | 抗npr1抗体及其用途 | |
| WO2011103702A1 (zh) | 一种全人源抗vegf单克隆抗体、其制备方法及用途 | |
| JP2023524811A5 (enExample) | ||
| JP2024503784A5 (enExample) | ||
| JP2023519100A5 (enExample) | ||
| JP2024542823A5 (enExample) | ||
| EP3585816A1 (en) | Cxcr2 antibodies and uses thereof | |
| US12606618B2 (en) | Antagonist anti-NPR1 antibodies and methods of use thereof | |
| JP2021523138A5 (enExample) | ||
| JP2024537284A5 (enExample) | ||
| JP6592600B2 (ja) | 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用 | |
| NZ773064B2 (en) | Anti-npr1 antibodies and uses thereof | |
| EP2727943A1 (en) | Trispecific antibodies against human EGFR, HER2 and HER3 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| TWI825687B (zh) | 抗ｃｘｃｒ２抗體及其用途 | |
| CN120230210A (zh) | 一组sh1同源簇全人源tsh受体阻断性单克隆抗体及其制备方法和应用 |